# US 2010/0074960 A1 · High-loading, controlled-release magnesium oral dosage forms and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074960 A1
- Document ID: US20100074960A1
- Status: Published application
- Kind: A1
- Application number: 12/467,883
- Filed: 2009-05-18
- Published: 2010-03-25
- Earliest claimed: 2008-05-19
- Assignees: Wynden Pharmaceuticals, Inc.
- Inventors: Stephen F. Brandon; Feng Zhang; Stuart Schoenherr
- Web page: https://patentgrep.com/patent/US20100074960A1

## CPC

- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2886: {having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer (of the type active core-drug layer-inactive layer A61K9/209)}
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

## Claims

### Claim 1

A high-loading dosage form for oral administration of a therapeutically effective amount of magnesium salt to a mammal comprising magnesium lactate present as from about 80% to about 95% by weight of the dosage form and one or more components present as from about 5% to about 20% by weight of the dosage form.

### Claim 2 (depends on 1)

The dosage form of claim 1, comprising at least about 9 mEq of magnesium lactate.

### Claim 3 (depends on 1)

The dosage form of claim 1, having a total weight of no more than about 1500 mg.

### Claim 4 (depends on 1)

The dosage form of claim 1, wherein the one or more components comprises a crosslinked acrylic acid-based polymer.

### Claim 5 (depends on 1)

The dosage form of claim 1, formed from a plurality of particles having a diameter of less than about 840 μm.

### Claim 6 (depends on 5)

The dosage form of claim 5, wherein the particles comprise magnesium lactate and a pharmaceutically acceptable carrier or diluent.

### Claim 7 (depends on 5)

The dosage form of claim 5, the particles further comprising a core having a first surface coating thereon.

### Claim 8 (depends on 7)

The dosage form of claim 7, wherein the first surface coating comprises a sustained release coating.

### Claim 9 (depends on 7)

The dosage form of claim 7, wherein the first surface coating comprises an enteric coating.

### Claim 10 (depends on 7)

The dosage form of claim 7, further comprising a second surface coating on the core.

### Claim 11 (depends on 10)

The dosage form of claim 10, wherein the second surface coating comprises a sustained release coating.

### Claim 12 (depends on 10)

The dosage form of claim 10, wherein the second surface coating comprises an enteric coating.

### Claim 13 (depends on 10)

The dosage form of claim 10, wherein the first surface coating comprises a barrier coating, and the second surface coating comprises an enteric coating.

### Claim 14

A controlled release dosage form for oral administration of a therapeutically effective amount of magnesium salt to a mammal comprising at least about 50% by weight of the dosage form of a magnesium salt, having an uncoated core dissolution profile under Tablet Dissolution Test characterized by no more than about 40% by weight magnesium salt released at 1 hour, at least about 50% by weight magnesium salt released at 6 hours, and at least about 85% by weight magnesium salt released at 10 hours.

### Claim 15 (depends on 14)

The dosage form of claim 14, wherein the dosage form controls the magnesium lactate release rate into the gastrointestinal tract of the mammal, the dosage form releasing the bulk of its magnesium lactate in a portion of the gastrointestinal tract distal to the duodenum.

### Claim 16 (depends on 14)

The dosage form of claim 14, wherein from about 20% to about 40% magnesium salt is released at 1 hour.

### Claim 17 (depends on 14)

The dosage form of claim 14, wherein from about 50% to about 80% magnesium salt is released at 6 hours.

### Claim 18 (depends on 14)

The dosage form of claim 14, comprising at least about 8 mEq of magnesium salt.

### Claim 19

A method of treating a disorder characterized by magnesium deficiency comprising administering to a mammal a therapeutically effective amount of an oral dosage form comprising at least about 80% by weight of a magnesium salt, thereby treating the disorder.

### Claim 20 (depends on 19)

The method of claim 19, wherein the dosage form comprises at least about 8 mEq of magnesium lactate present as from about 80% to about 95% by weight of the dosage form and one or more components present as from about 5% to about 20% by weight of the dosage form.

### Claim 21 (depends on 19)

The method of claim 19, wherein the amount is sufficient to restore depleted serum magnesium levels to a therapeutically acceptable level.

### Claim 22 (depends on 19)

The method of claim 19, wherein the amount is sufficient to restore depleted intracellular magnesium levels to a concentration of at least about 33.9 mEq/IU.

### Claim 23 (depends on 22)

The method of claim 22, wherein the intracellular magnesium levels are restored to a concentration of at least 33.9 mEq/IU within about 51 hours after administration.

### Claim 24

A method of preventing or alleviating low magnesium levels comprising co-administering to a mammal a therapeutically effective amount of an oral dosage form comprising at least about 80% by weight of a magnesium salt and a drug having a known side-effect of decreasing intracellular magnesium levels, thereby preventing or alleviating the low magnesium levels.

### Claim 25 (depends on 24)

The method of claim 24, wherein the drug has a known side-effect of decreasing magnesium serum levels.

### Claim 26 (depends on 24)

The method of claim 24, wherein the drug is a diuretic, an immunosuppressant, a chemotherapeutic agent, or an antibiotic.

### Claim 27

A kit comprising an oral dosage form comprising at least about 80% by weight of a magnesium salt and a drug having a known side-effect of decreasing intracellular magnesium levels.

### Claim 28 (depends on 27)

The kit of claim 27, wherein the magnesium salt comprises magnesium L-lactate dihydrate.

### Claim 29

A method of preventing or alleviating low magnesium levels comprising co-administering to a mammal a therapeutically effective amount of an oral dosage form comprising at least about 80% by weight of a magnesium salt and a drug known to treat a disorder associated with decreasing intracellular magnesium levels, thereby preventing or alleviating the low magnesium levels.

### Claim 30 (depends on 29)

The method of claim 29, wherein the disorder is associated with decreasing magnesium serum levels.

### Claim 31 (depends on 29)

The method of claim 29, wherein the drug is a diuretic, an immunosuppressant, a chemotherapeutic agent, or an antibiotic.

### Claim 32

A kit comprising an oral dosage form comprising at least about 80% by weight of a magnesium salt and a drug known to treat a disorder associated with decreasing intracellular magnesium levels.

### Claim 33

A method of making a controlled release dosage form for oral administration of a therapeutically effective amount of magnesium salt to a mammal comprising the step of compressing a blend of granulated magnesium salt and one or more components at a pressure sufficient to form a dosage form comprising at least about 80% by weight of the magnesium salt.

### Claim 34 (depends on 33)

The method of claim 33, wherein the magnesium salt has been prepared by fluid bed granulation.
